Overview
Pharmaceutical

Mochida Pharmaceutical Co.,Ltd.

Mochida Pharmaceutical is a Japanese pharmaceutical company engaged in the manufacture and sale of ethical pharmaceuticals and healthcare products. Its core pharmaceutical business covers prescription drugs developed with a focus on unmet medical needs, including areas such as inflammatory bowel disease, while its healthcare segment markets consumer health products through subsidiary Mochida Healthcare Co., Ltd. The company also operates a biomaterials business, and leverages its group manufacturing subsidiary, Mochida Pharmaceutical Factory Co., Ltd., for production across all segments.

Market Cap
¥116B
US$741M
EV
¥60.8B
US$388M
Stock¥3,285▲+0.61%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
4.3
x
LTM EV/EBIT
5.5
x
LTM PER
12.6
x
LTM PBR
0.8
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-14.5%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
116BUS$741MMarket Cap10.3BUS$65.9M+ Debt25.4BUS$162M− Cash40.3BUS$257M− Inv. Sec.60.8BUS$388MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
110US$703M'22/3103US$659M'23/3103US$656M'24/3105US$671M'25/3117US$746M'26/3
EBITDA 5Y (¥B)
17.1US$109M'22/311.2US$71.3M'23/38.61US$54.9M'24/311.1US$70.6M'25/313.1US$83.7M'26/3
Net Income 5Y (¥B)
10.6US$67.4M'22/36.65US$42.4M'23/34.55US$29.0M'24/35.69US$36.3M'25/37.90US$50.4M'26/3
Capital Structure
93%
EquityD/E 0.07xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
64.9US$414M'22/361.3US$391M'23/349.4US$315M'24/360.2US$384M0.69US$4.37M'25/367.3US$429M10.3US$65.9M'26/3
Shareholders
Top 10 hold 51.1%
1
Mochida Memorial Foundation for Medical and Pharmaceutical Research
16.05%
2
The Master Trust Bank of Japan, Ltd. (Trust Account)
8.41%
3
Princess Takamatsu Cancer Research Fund
4.75%
4
MUFG Bank, Ltd.
4.48%
5
Mizuho Trust & Banking Co., Ltd. (Retirement Benefit Trust, Mizuho Bank, Ltd. Account; Re-trustee: Custody Bank of Japan, Ltd.)
4.05%
6
Nissui Corporation
3.39%
7
Naoyuki MOCHIDA
2.89%
8
Takeshi MOCHIDA
2.68%
9
Kazue MOCHIDA
2.22%
10
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
2.21%
Management
16 officers
Naoyuki MOCHIDA
Representative Director, President
Apr 1981 Joined Mochida Pharmaceutical Co., Ltd. May 1986 Completed MBA program, Indiana University Graduate School of Business Apr 1988 Joined Ajinomoto Co., Inc. Apr 1991 Rejoined Mochida Pharmaceutical Co., Ltd. Apr 1996 General Manager, Development Planning Department Apr 1997 General Manager, Finance Department Jun 1997 Director Jan 1998 Senior Managing Director; General Manager, Management Planning Office Jan 1999 Representative Director, President (current) Apr 2010 Vice Chairman, Mochida Memorial Foundation for Medical and Pharmaceutical Research Jun 2016 Chairman, Mochida Memorial Foundation for Medical and Pharmaceutical Research (current)
1958-08-06
Junichi SAKAKI
Representative Director, Senior Managing Director, Senior Managing Executive Officer; in charge of Research, Biomaterials Business, Pharmaceutical Sales, Mochida Pharmaceutical Manufacturing, and Mochida Healthcare
Mar 1993 Joined Ciba-Geigy Japan Ltd. Jul 2005 Head of Research Strategy and Alliances, Novartis Pharma K.K. Dec 2006 Joined Banyu Pharmaceutical Co., Ltd.; Director, Chemistry Research Department, Tsukuba Research Laboratories Jul 2009 Joined Mochida Pharmaceutical Co., Ltd.; General Manager, Research Planning and Promotion Department Apr 2010 Director, Drug Discovery Research Laboratories Jun 2012 Executive Officer; Deputy General Manager, Business Development Division Jun 2014 Director, Executive Officer; in charge of Business Development Jun 2016 Director, Managing Executive Officer Oct 2018 Director, Managing Executive Officer; in charge of Business Development and Biomaterials Business Jun 2021 Director, Senior Managing Executive Officer Jun 2022 In charge of Business Development; responsible for Biomaterials Business Jan 2023 In charge of Business Development and Business Promotion; responsible for Biomaterials Business Jun 2023 In charge of Business Development and Business Promotion; responsible for Biomaterials Business Jun 2024 In charge of Business Development and Business Promotion; responsible for Biomaterials Business Jun 2025 Representative Director, Senior Managing Director, Senior Managing Executive Officer (current); in charge of Research, Drug Development, Business Development, Business Promotion, Biomaterials Business, Pharmaceutical Sales, Mochida Pharmaceutical Manufacturing, and Mochida Healthcare Jun 2026 In charge of Research, Biomaterials Business, Pharmaceutical Sales, Mochida Pharmaceutical Manufacturing, and Mochida Healthcare (current)
1960-10-23
Motoi MITSUISHI
Representative Director, Senior Managing Director, Senior Managing Executive Officer; in charge of Corporate Planning and Administration, Strategic Alliances, Legal, and Audit; responsible for Reliability Assurance
Apr 1987 Joined The Mitsubishi Bank, Ltd. May 2012 General Manager, Thailand, and Branch Manager, Bangkok Branch, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2013 Executive Officer; General Manager, Thailand, and Branch Manager, Bangkok Branch, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jul 2015 Executive Officer; Deputy General Manager, Asia and Oceania Division (special assignment); General Manager, Asia and Oceania Business Department; Branch Manager, Singapore Branch, The Bank of Tokyo-Mitsubishi UFJ, Ltd. May 2017 Managing Executive Officer; General Manager, Transaction Banking Division, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2019 Representative Director, Senior Managing Director, Mitsubishi UFJ Research and Consulting Co., Ltd. Jun 2020 Outside Audit & Supervisory Board Member, The Nanto Bank, Ltd. May 2023 Advisor, Mochida Pharmaceutical Co., Ltd. Jun 2023 Director, Managing Executive Officer; in charge of Corporate Planning and Administration and TechnoNet; General Manager, Corporate Planning and Administration Division Apr 2024 In charge of Corporate Planning and Administration; General Manager, Corporate Planning and Administration Division Jun 2024 Director, Senior Managing Executive Officer Jun 2025 Representative Director, Senior Managing Director, Senior Managing Executive Officer (current); in charge of Corporate Planning and Administration, Audit, and Reliability Assurance; General Manager, Corporate Planning and Administration Division Oct 2025 In charge of Corporate Planning and Administration, Strategic Alliances, and Audit; responsible for Reliability Assurance; General Manager, Corporate Planning and Administration Division Jun 2026 In charge of Corporate Planning and Administration, Strategic Alliances, Legal, and Audit; responsible for Reliability Assurance (current)
1963-09-23
Junichi NEZU
Director, Managing Executive Officer; in charge of Research; responsible for Drug Development
Apr 1991 Joined Chugai Pharmaceutical Co., Ltd. Jul 2012 Research Head, Chugai Pharmabody Research Pte. Ltd. (Singapore) Apr 2018 Senior Fellow and General Manager, Research Division; General Manager, Drug Discovery Pharmacology Department, Chugai Pharmaceutical Co., Ltd. Apr 2020 Executive Officer, General Manager, Research Division, Chugai Pharmaceutical Co., Ltd. Jan 2021 Executive Officer; General Manager, R&D Portfolio Department, Project Lifecycle Management Unit, Chugai Pharmaceutical Co., Ltd. Jul 2023 Joined the Company; attached to Research Division, in charge of Research Aug 2023 Managing Executive Officer; in charge of Research Jun 2024 Director, Managing Executive Officer (current); in charge of Research; responsible for Drug Development (current)
1966-11-03
Kenji MIYAJIMA
Director, Managing Executive Officer; in charge of Pharmaceutical Sales and Mochida Healthcare
Apr 1990 Joined the Company Apr 2017 General Manager, Hiroshima Branch Apr 2020 General Manager, Osaka Branch Apr 2021 Deputy General Manager, Pharmaceutical Sales Division Jun 2021 Executive Officer Apr 2022 General Manager, Pharmaceutical Sales Division Jun 2025 Director, Managing Executive Officer; in charge of Pharmaceutical Sales (current) Jun 2026 In charge of Pharmaceutical Sales and Mochida Healthcare (current)
1967-09-23
Takeshi MOCHIDA
Director, Managing Executive Officer; in charge of Business Development and Business Promotion
Apr 1992 Joined Mizuho Trust & Banking Co., Ltd. Apr 2009 Joined the Company Apr 2015 General Manager, Marketing Department Jun 2017 Executive Officer Oct 2019 Executive Officer; Deputy General Manager, Pharmaceutical Sales Division Jun 2020 Executive Officer; Deputy General Manager, Pharmaceutical Development Division (in charge of Development Planning and Promotion and Medical Affairs) Jun 2026 Director, Managing Executive Officer; in charge of Business Development and Business Promotion (current)
1969-04-30
Naka SAKATA
Director and Counselor
Apr 1982 Joined The Mitsubishi Bank, Ltd. May 2007 General Manager, Syndication Department, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Feb 2009 General Manager, Middle East Region, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2011 Advisor, the Company Jun 2011 Director, Executive Officer; Deputy in charge of Corporate Planning and Administration Apr 2012 Deputy in charge of Corporate Planning and Administration; General Manager, Corporate Planning and Administration Division Jun 2012 In charge of Corporate Planning and Administration; General Manager, Corporate Planning and Administration Division Jun 2013 Director, Managing Executive Officer Jun 2016 Representative Director, Senior Managing Director, Senior Managing Executive Officer; in charge of Corporate Planning and Administration, Audit, and Corporate Ethics Jun 2017 Assistant to the President; in charge of general operations Jun 2021 Representative Director, Executive Vice President, Executive Vice President Executive Officer Jun 2025 Director and Counselor (current)
1959-12-28
Tomoaki SONODA
Director
Apr 2004 Registered as Certified Public Accountant (current) Apr 2006 Professor, Faculty of Business and Commerce, Keio University (current) Oct 2009 Member, Government Contract Monitoring Committee, Ministry of Internal Affairs and Communications (current) Apr 2018 Visiting Professor, Musashino University (current) Jan 2020 Member, Third Bidding Monitoring Committee, Ministry of Finance (current) Jun 2022 Director, the Company (current) Sep 2025 Member of the Board of Councillors, Keio Gijuku (current)
1961-07-01
Yoshiaki YOSHIKAWA
Director
Apr 1977 Joined Mitsubishi Corporation Apr 2008 Executive Officer, General Manager, Business Administration Department, Mitsubishi Corporation Apr 2010 Executive Officer; Deputy General Manager, Europe, Africa, Middle East and CIS, Mitsubishi Corporation Apr 2013 Managing Executive Officer; General Manager, Middle East and Central Asia, Mitsubishi Corporation Oct 2016 Senior Managing Executive Officer, Mitsubishi Research Institute, Inc. Dec 2016 Representative Director, Executive Vice President, Mitsubishi Research Institute, Inc. Jun 2017 Member, Management Council, Fukushima Medical University Dec 2020 Full-time Advisor, Mitsubishi Research Institute, Inc. Apr 2021 Visiting Professor, Department of Business Design, Showa Women's University; Specially Appointed Research Fellow, Institute of Contemporary Business Studies (current) Jan 2022 Advisor, Mitsubishi Research Institute, Inc. Jun 2022 Outside Director, Azbil Corporation (current) Jun 2023 Chairman, Japan-Singapore Association (current) Jun 2023 Director, the Company (current) May 2025 Member of the Board of Councillors, Showa Women's University (current)
1953-06-23
Mami KOBAYASHI
Director
Apr 1987 Joined Nihon Keizai Shimbun, Inc. Sep 1988 Joined The Asahi Shimbun Company Oct 1990 Joined McKinsey & Company Dec 1994 Joined United Technologies Corporation (U.S.) Oct 2002 Library Director, Cultural Business Division, Mori Building Co., Ltd. Apr 2010 Library Advisor, Cultural Business Division, Mori Building Co., Ltd. Jun 2024 Director, the Company (current)
1964-09-20
Sanae TANAKA
Director
Apr 1989 Registered as Attorney-at-Law (current) Sep 1991 Founded Tanaka Sanae Law Office; Representative (current) Mar 2011 Outside Director, Noevir Holdings Co., Ltd. Mar 2015 Outside Director, Pilot Corporation May 2015 Outside Director, Shochiku Co., Ltd. Mar 2023 Outside Audit & Supervisory Board Member, Asahi Group Holdings, Ltd. Jun 2023 Outside Director, TV Asahi Holdings Corporation (current) Mar 2025 Outside Director, Asahi Group Holdings, Ltd. (current) Jun 2025 Director, the Company (current)
1962-07-15
Yoshiharu HASHIMOTO
Full-time Audit & Supervisory Board Member
Apr 1985 Joined The Mitsubishi Bank, Ltd. Jan 2009 Yotsuya Branch Manager, The Bank of Tokyo-Mitsubishi UFJ, Ltd. May 2011 Senior General Manager, Osaka Business Division II, Osaka Business Headquarters, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2013 General Manager, Business Development Department, Sharp Corporation Jun 2016 Full-time Audit & Supervisory Board Member, Mitsubishi UFJ Capital Co., Ltd. Jun 2017 Joined the Company Jun 2017 Full-time Audit & Supervisory Board Member Jun 2019 Director, Executive Officer; in charge of Corporate Planning and Administration and TechnoNet; General Manager, Corporate Planning and Administration Division Jun 2022 Director, Managing Executive Officer Jun 2023 Full-time Audit & Supervisory Board Member (current)
1963-01-23
Kyosuke WAGAI
Audit & Supervisory Board Member
Oct 1977 Joined Tohmatsu & Aoki Audit Corporation Sep 1982 Registered as Certified Public Accountant (current) Jul 1991 Partner, Tohmatsu & Co. Jul 2010 Managing Director, Japanese Institute of Certified Public Accountants May 2016 Resigned from Deloitte Tohmatsu Audit (formerly Tohmatsu Audit Corporation) Jun 2016 Audit & Supervisory Board Member, the Company (current) Jul 2016 Auditor, Japanese Institute of Certified Public Accountants Jun 2017 Outside Audit & Supervisory Board Member, Tokyo Electron Limited Jun 2017 Representative Director and Chairman, XBRL Japan (current) Jun 2023 Auditor, Japan Federation of Shihoshoshi Associations (current)
1953-02-05
Akiko SUZUKI
Audit & Supervisory Board Member
Apr 1974 Registered as Attorney-at-Law; joined Anderson Mori & Tomotsune (current) Sep 1990 Joined the Company Sep 1998 Joined Tokyo Eiwa Law Office Sep 2002 Joined Ohebashi Law Office, Tokyo Office; Partner (Associate Attorney) Jun 2019 Audit & Supervisory Board Member, the Company (current)
1949-03-05
Yoshifumi MIYATA
Audit & Supervisory Board Member
Apr 1978 Joined The Dai-ichi Life Insurance Company, Limited Apr 2006 Executive Officer; General Manager, Corporate Financial Division, The Dai-ichi Life Insurance Company, Limited Apr 2009 Managing Executive Officer, The Dai-ichi Life Insurance Company, Limited Jun 2010 Outside Audit & Supervisory Board Member, Tsugami Corporation Jun 2012 Representative Director, Executive Vice President, Trust & Custody Services Bank, Ltd. Oct 2018 Outside Director, Welnest Communications Co., Ltd. (current) Jun 2021 Audit & Supervisory Board Member, the Company (current)
1952-10-19
Reiko NAKANO
Full-time Audit & Supervisory Board Member
Apr 1986 Joined the Company Apr 2015 General Manager, Intellectual Property Department Jun 2018 Executive Officer Apr 2022 Deputy General Manager, Business Development Division Jun 2025 Deputy General Manager, Business Development Division Jun 2026 Full-time Audit & Supervisory Board Member (current)
1963-06-08
Large Shareholding Reports
Mochida Memorial Foundation for Medical and Pharmaceutical Research
2026-04-10
14.00%→15.63%
Annual report (as of 2026-03-31): 16.05%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-03
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-24
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-04-10
Large Shareholding Report
TDnet
2026-03-30
Q3 Earnings Flash
FY ending Mar 2026
TDnet
2026-02-06
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-10
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-01
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-27
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-07
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-11
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-02
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-27
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-09
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-29
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-05
Quarterly Securities Report
EDINET
2022-06-29
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-06-29
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →